Article
Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) - 1 Aug 2020
Cui Wanyuan, Franchini Fanny, Alexander Marliese, Officer Ann, Wong Hui-Li, IJzerman Maarten, Desai Jayesh, Solomon Benjamin J
Abstract excerpt
BACKGROUND: KRAS mutations are found in 20-30 % of non-small cell lung cancers (NSCLC) and were traditionally considered undruggable. KRASG12C mutation confers sensitivity to KRASG12C covalent inhibitors, however its prognostic impact remains unclear. This study assesses the frequency, clinical features, prevalence of brain metastases and outcomes in KRASG12C NSCLC in a real-world setting. METHODS: Patients...
Topics
- Carcinoma, Non-Small-Cell Lung
- Humans
- Lung Neoplasms
- Mutation
- Prospective Studies
- Protein-Tyrosine Kinases
- Proto-Oncogene Proteins
- Proto-Oncogene Proteins p21(ras)